Overview
This educational conference, Clinical Updates from San Diego on Hematologic Malignancies, is a pre-session to the ACCC 50th Annual Meeting & Cancer Center Business Summit and is designed to equip hematologic malignancy practitioners with practical tools for implementing cutting-edge data into patient care. The event will spotlight the application of state-of-the-art treatment strategies in clinical practice including advancements in CAR T-cell therapy, bispecific agents, and antibody-drug conjugates, as well as optimal management of associated adverse events.
Attendees will have the opportunity to engage with renowned experts, gaining insights into managing hematologic malignancies: leukemias, lymphomas, myeloma, MDS, and MPNs. Throughout the meeting, cases from community providers and panel discussions will provide a platform for debate and peer exchange on challenging, real-world clinical situations.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Outline prognostic and predictive markers identified in patients with hematologic malignancies that inform risk stratification and decision-making
- Report safety and efficacy findings from hematologic malignancy trials that assessed emerging treatment strategies
- Determine how to identify and manage treatment-related toxicities among patients with hematologic malignancies
- Place recent evidence from clinical trials in the context of evolving care paradigms for hematologic malignancies
Benefits of Attending:
- Gain practical tools to translate emerging data into effective therapies
- Stay abreast of the latest developments in hematologic malignancy treatment
- Glean insights and perspectives on managing various hematologic malignancies from internationally renowned experts in the field
- Acquire knowledge on applying state-of-the-art treatment strategies to clinical practice settings
- Participate in panel discussions that facilitate debate and peer exchange on challenging clinical scenarios
Hot Topics:
- Practical tools for patient care
- CAR-T-cell therapy
- Bispecific agents
- Antibody-drug conjugates
- Recognizing AEs from novel agents
Naval Daver, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Click the button below to view all faculty presenters.
Seema Bhat, MD
Associate Professor
Division of Hematology
The Ohio State University
Columbus, OH
Joshua Brody, MD
Director
Lymphoma Immunotherapy Program
Ichan School of Medicine at Mount Sinai
New York, NY
Caitlin Costello, MD
Associate Clinical Professor of Medicine
Moores Cancer Center
UC San Diego
La Jolla, CA
Guillermo Garcia-Manero, MD
McCredie Professor of Medicine
Vice Chair Department of Leukemia
Chief, Section of MDS
Houston, TX
Brian Hill, MD, PhD
Director, Lymphoid Malignancies Program
Staff Physician, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Assistant Professor, Cleveland Clinic
Cleveland, OH
Aaron Logan, MD, PhD
Associate Professor of Clinical Medicine, Division of Hematology/Oncology
University of California San Francisco
San Francisco, CA
John Mascarenhas, MD
Professor of Medicine
Director, Center of Excellence in Blood Cancers and Myeloid Disorders
Tisch Cancer Institute
Icahn School of Medicine of Mount Sinai
New York, NY
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 8.25 Contact Hours.